Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sarepta Therapeutics Inc (SRPT): Two Viewpoints On The FDA News

Sarepta Therapeutics Inc (NASDAQ:SRPT) announced yesterday after the market closed that the U.S. Food and Drug Administration requested additional information before it could make a decision on acceptability of an accelerated approval filing for its Duchenne muscular dystrophy drug eteplirsen. Sarepta shares were down more than 12% in early trading.

This market reaction reflects a decidedly negative view of the FDA news, but is that outlook on target? Here are two ways to look at it.

Bad news?
Sarepta Therapeutics Inc (NASDAQ:SRPT)If the FDA needs more information after receiving a briefing summary about the eteplirsen dataset and meeting with Sarepta Therapeutics Inc (NASDAQ:SRPT) representatives, things likely don’t look great for accelerated approval, right? Surely Sarepta’s shares would drop in the double-digits only if the news was bad.

The FDA asked for two additional written summaries. The first was for “a coherent and comprehensive summary to support dystrophin as a surrogate.” The second was for “a detailed discussion of all clinical outcomes in the eteplirsen study.”

Pessimists would say that the first request could indicate skepticism by the FDA that the dystrophin results from the phase 2 study of eteplirsen can be used as an acceptable surrogate for clinical efficacy. They would also probably note that the second request could reflect negatively on the small size of the study, which included only 12 patients.

Even if this reading between the lines isn’t on target, the request for additional information knocks the winds out of the sails of those who thought that accelerated approval was a slam dunk. That clearly isn’t the case now.

Good news?
Could there actually be good news in spite of the market’s reaction? Possibly.

For one thing, the FDA could have just said “no way.” It didn’t. The agency specifically stated that it has not made a final decision and would only make one after it reviews the supplemental information from Sarepta Therapeutics Inc (NASDAQ:SRPT).

Sarepta management thinks that their detailed discussions with the FDA went well. These talks, though, went into greater detail than the briefing documents that had been supplied earlier. It seems reasonable that the FDA could want more information after these more in-depth discussions.

The second potential piece of good news stems from the nature of the FDA request itself. As Baird analyst Brian Skorney pointed out in the conference call discussion last night, the questions that the FDA is asking typically are part of the actual New Drug Application review.

The fact that officials are wanting the data earlier could be positive. As Sarepta CEO Chris Garabedian said, “It seems that they’re digging a little deeper here than they would normally, and almost bridging it into a review of our data.”

If this is the case, a go-ahead from the FDA for Sarepta Therapeutics Inc (NASDAQ:SRPT) to submit eteplirsen for accelerated approval should mean that the chances of ultimate approval are high.

Foolish take
What’s the real story? I think it could go either way for accelerated approval. Right now, all anyone can do is speculate.

All along, my view was that Sarepta probably would file for and ultimately gain accelerated approval. The FDA’s request for additional information doesn’t dismantle that view. On the surface, the news appears to be bad. However, there could be a silver lining.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.